Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · IEX Real-Time Price · USD
2.730
-0.030 (-1.09%)
At close: Jul 19, 2024, 4:00 PM
2.650
-0.080 (-2.93%)
Pre-market: Jul 22, 2024, 8:51 AM EDT
Lexaria Bioscience Employees
Lexaria Bioscience had 5 employees as of August 31, 2023. The number of employees decreased by 2 or -28.57% compared to the previous year.
Employees
5
Change (1Y)
-2
Growth (1Y)
-28.57%
Revenue / Employee
$75,369
Profits / Employee
-$971,118
Market Cap
43.16M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Aug 31, 2023 | 5 | -2 | -28.57% |
Aug 31, 2022 | 7 | 1 | 16.67% |
Aug 31, 2021 | 6 | 2 | 50.00% |
Aug 31, 2020 | 4 | - | - |
Related Stocks
Company Name | Employees |
---|---|
NeueHealth | 1,252 |
Qilian International Holding Group | 298 |
Fortress Biotech | 186 |
BioXcel Therapeutics | 74 |
OncoCyte | 46 |
Envoy Medical | 34 |
Movano | 30 |
Tempest Therapeutics | 17 |
LEXX News
- 4 days ago - Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study - Accesswire
- 5 days ago - Lexaria Preparing For Strategic Growth - Accesswire
- 13 days ago - Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study - Accesswire
- 14 days ago - Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy - Accesswire
- 4 weeks ago - Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study - Accesswire
- 6 weeks ago - Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study - Accesswire
- 2 months ago - Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study - Accesswire
- 2 months ago - Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study - Accesswire